Abstract
Goals of work
Although many patients with ovarian cancer achieve favorable responses to primary chemotherapy, the majority of women will experience recurrence of their cancer. Selection of second- or third-line chemotherapy ultimately depends on patient preferences for different side effects. To better understand this process, we evaluated preferences and symptom distress in patients with ovarian cancer.
Patients and methods
A total of 70 women with ovarian cancer who had previously received at least three cycles of platinum-based chemotherapy and currently undergoing chemotherapy for newly diagnosed or recurrent disease were interviewed in an outpatient chemotherapy clinic. The patients were asked to rank order 27 health states using a modified visual analog scale and to complete the Memorial Symptom Assessment Scale (MSAS).
Main results
Most favorable health states included perfect health, clinical remission and complete control of chemotherapy-induced nausea and vomiting (CINV). Least favorable health states included more severe CINV health states and death. Patients on first-line chemotherapy had less symptom distress, and rated sexual dysfunction, fatigue and memory loss more favorably than patients on second- or third-line chemotherapy (P<0.05). Married patients generally had less symptom distress compared to patients who were not married, but married patients indicated more distress with sexual dysfunction (P=0.04). Married patients rated alopecia less favorably than unmarried patients (P=0.03), but married patients viewed certain CINV health states more favorably (P=0.02–0.04).
Conclusions
CINV remains one of the most dreaded side effects of chemotherapy. Separate preference profiles exist for patients with newly diagnosed and recurrent disease, as well as for married versus unmarried patients. While MSAS scores and VAS rankings showed consistency across some health states, this was not true for CINV, suggesting that current symptom status may only influence patient preferences for selected side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agarwal R, Kaye SG (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502–516
Borjeson S, Hursti T, Peterson C, Fredikson M, Furst CJ, Avall-Lundqvist E, Steineck G (1997) Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs 20(4):260–266
Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of chemotherapy. Cancer 95:155–163
Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208
de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76(8):1055–1061
Drummond MF, O’Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes (2nd edn). Oxford University Press, New York
Griffen AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195
Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T (1996) Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4:435–439
Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT (1999) Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Practice 7(2):59–65
McGarvey EL, Baum LD, Pinkerton RC, Rogers LM (2001) Psychological sequelae and alopecia among women with cancer. Cancer Practice 9(6):283–289
Moss C, Kaye SB (2002) Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 38:1701–1707
Münstedt K, Manthey N, Sachsse S, Vahrson H (1997) Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 5:139–143
Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L, Scher H (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A(9):1326–1336
Stiggelbout AM, De Haes JCJM (2001) Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 19:220–230
Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM (2002) Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87:118–128
Torrance GW, Feeny D, Furlong W (2001) Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 21:329–334
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, C.C., Bodurka, D.C., Weaver, C.B. et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13, 219–227 (2005). https://doi.org/10.1007/s00520-004-0710-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-004-0710-6